Searched for
ANTIBODY DRUG CONJUGATES
Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Nandini Piramal warns prolonged West Asia war may raise input costsGeopolitical tensions in West Asia are manageable now. However, a prolonged US-Israel war against Iran could raise costs for petrochemical-...
- Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipelineGilead is making headlines with its planned acquisition of Tubulis GmbH, a Germany-based company, for a maximum of five billion dollars. Th...
- Trump tariffs hit patented drugs: Jefferies, Nomura explain impact on pharma stocksThe US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. S...
- Cancer drug makers seek 50% price hike as platinum surge hits production viabilityLocal drug manufacturers are struggling to produce essential cancer medicines like carboplatin and cisplatin due to a significant surge in ...
- Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas TambeBiocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...
- US Stocks: Kodiak Sciences shares soar 68% after eye drug succeeds in late-stage studyShares of Kodiak Sciences surged 68.6% to their highest in more than four years on Thursday after the drug developer's experimental drug me...
- AstraZeneca, Gilead vie for edge in race to treat tough breast cancerNew data from Europe's biggest oncology meeting reveals a high-stakes race for patients with a tough breast cancer. Astra and Daiichi's Dat...
- AstraZeneca gets regulator's nod to market cancer drug in IndiaAstraZeneca Pharma has secured approval from India's drug regulator for its cancer treatment Trastuzumab Deruxtecan. This drug is now appro...
- Piramal Healthcare targets $2 bn revenue by FY30, to focus on organic expansion: Chairperson Nandini PiramalPiramal Healthcare prioritizes organic growth for the next 4-5 years. The company will explore licensing and product acquisitions in comple...
- AstraZeneca, Daiichi Drug gets broad tumor approval in USEnhertu, a collaboration between AstraZeneca and Daiichi Sankyo, gains FDA approval for treating HER2-positive solid tumors spread througho...
- AstraZeneca bets on licencing deals, public-private partnerships for India growthBritish-Swedish drugmaker AstraZeneca is set to launch 15 new products in India from 2023 to 2025, focusing on oncology, cardiovascular, re...
- Piramal Pharma invests Rs 102 crore in Yapan Bio for significant minority stakeBiologics capabilities can be synergistic with the company's anti-body drug conjugation capabilities; specifically, for customers who prefe...
- SPARC enters licensing pact with Biomodifying for licensing of novel drug targets against cancer“This is an important milestone for SPARC. The licensing of antibodies from Biomodifying will assist us in our endeavour to transition SPAR...
- Cadila Healthcare Q1 results: Net profit rises 29% to Rs 587 crConsolidated total revenue from operations stood at Rs 4,025.4 crore for the quarter under consideration against Rs 3,514.6 crore for the s...
- Zydus Cadila launches breast cancer treatment drug Ujvira"In a step that can significantly reduce treatment cost by almost 80 per cent, the drug is being offered at Rs 32,495 for a 100 mg vial. Th...
- Piramal Healthcare UK Ltd invests £2.0 million in ScotlandThe new facility is expected to create up to 20 new high-skill job roles, backed by £200,000 Regional Selective Assistance funding.
- Piramal Healthcare signs pact with Japan's Fujifilm DiosynthMumbai-based Piramal Healthcare has teamed up with Japan's Fujifilm Diosynth for a contract manufacturing deal that would look to develop a...
- Biocon to partner US-based firm for developing cancer drugBiotech major Biocon Ltd on Thursday said it will enter into a partnership with a US-based biotechnology company, Iatrica, to develop drug ...
Load More
